EGFR and head and neck squamous cell carcinoma: Understanding of the mutational and genomic landscape of HNSCC [32] has enabled better use of therapies such as EGFR inhibitors and, more recently, immune checkpoint inhibitors [33], and will continue to drive innovations in targeted druggable approaches.